{"cluster": 43, "subcluster": 21, "abstract_summ": "During severe inflammatory coronavirus infectious disease (CoVID\u201019) pandemic and based on evidence on COVID\u201019 epidemiology, patients with primary cutaneous lymphomas (PCLs) have risk for developing complicated COVID\u201019 infections in consideration of their older age (majority above 60) and their potential underlying predisposing conditions (e.g. hypertension, diabetes).(1,2,3) Moreover, PCL patients with aggressive biologic behavior should be carefully monitored according to guidelines for patients with neoplastic disease.we read with great interest the article entitled \u201cShould SARS\u2010CoV\u20102 influence immunosuppressive therapy for autoimmune blistering diseases?We read with great interest the publication of Messina et al (1) reporting the first case of SARS\u2010CoV2 infection in a young patient of 32\u2010year\u2010old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)\u201023(2).The patient contracted the SARS\u2010CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea.The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID\u201019, in order to better quantify the risk of infection under immunosuppressive therapy.This is the first report of COronaVIrus DIsease 2019 (COVID\u201019) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine).Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.", "title_summ": "Management of primary cutaneous lymphoma patients during COVID\u201019 pandemic: EORTC CLTF guidelines Maarten VermeerOccurrence of SARS\u2010CoV\u20102 during mycophenolate mofetil treatment for pemphigusCID\u201019 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care managementImprovement of SARS\u2010CoV2 symptoms following Guselkumab injection in a psoriatic patient", "title_abstract_phrases": "Management of primary cutaneous lymphoma patients during COVID\u201019 pandemic: EORTC CLTF guidelines Maarten VermeerDuring severe inflammatory coronavirus infectious disease (CoVID\u201019) pandemic and based on evidence on COVID\u201019 epidemiology, patients with primary cutaneous lymphomas (PCLs) have risk for developing complicated COVID\u201019 infections in consideration of their older age (majority above 60) and their potential underlying predisposing conditions (e.g. hypertension, diabetes).(1,2,3) Moreover, PCL patients with aggressive biologic behavior should be carefully monitored according to guidelines for patients with neoplastic disease.Improvement of SARS\u2010CoV2 symptoms following Guselkumab injection in a psoriatic patientWe read with great interest the publication of Messina et al (1) reporting the first case of SARS\u2010CoV2 infection in a young patient of 32\u2010year\u2010old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)\u201023(2).The patient contracted the SARS\u2010CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea.The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID\u201019, in order to better quantify the risk of infection under immunosuppressive therapy.CID\u201019 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care managementNovel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population.This is the first report of COronaVIrus DIsease 2019 (COVID\u201019) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine)."}